A Phase 2a, Randomized, Open-label, Active Control, Multi-Center Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Bleselumab (Primary) ; Basiliximab; Methylprednisolone; Mycophenolate mofetil; Mycophenolate mofetil; Prednisone; Tacrolimus; Tacrolimus
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 20 Apr 2017 Status changed from active, no longer recruiting to completed.
- 05 Feb 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.
- 05 Feb 2016 Planned primary completion date changed from 1 Dec 2016 to 1 Feb 2017 as reported by ClinicalTrials.gov.